These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9748592)

  • 1. The response of eukaryotic topoisomerases to DNA damage.
    Kingma PS; Osheroff N
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):223-32. PubMed ID: 9748592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA topoisomerases as targets for anticancer drugs.
    Topcu Z
    J Clin Pharm Ther; 2001 Dec; 26(6):405-16. PubMed ID: 11722677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
    Thielmann HW; Popanda O; Gersbach H; Gilberg F
    Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions.
    Sabourin M; Osheroff N
    Nucleic Acids Res; 2000 May; 28(9):1947-54. PubMed ID: 10756196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
    Marx G; Zhou H; Graves DE; Osheroff N
    Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.
    Wilstermann AM; Osheroff N
    Curr Top Med Chem; 2003; 3(3):321-38. PubMed ID: 12570766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
    Boege F
    Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases.
    Schmidt BH; Burgin AB; Deweese JE; Osheroff N; Berger JM
    Nature; 2010 Jun; 465(7298):641-4. PubMed ID: 20485342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage.
    Kingma PS; Osheroff N
    J Biol Chem; 1997 Mar; 272(11):7488-93. PubMed ID: 9054451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous DNA lesions poison human topoisomerase IIalpha and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints.
    Kingma PS; Greider CA; Osheroff N
    Biochemistry; 1997 May; 36(20):5934-9. PubMed ID: 9166762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symposium: downstream from topoisomerase-DNA lesions: life-or-death consequences for the cell.
    Kohn KW; Andoh T
    Cell Biochem Biophys; 2000; 33(2):171-3. PubMed ID: 11325036
    [No Abstract]   [Full Text] [Related]  

  • 12. N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison.
    Bender RP; Lindsey RH; Burden DA; Osheroff N
    Biochemistry; 2004 Mar; 43(12):3731-9. PubMed ID: 15035644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerases: from a laboratory curiosity to a subject in cancer chemotherapy.
    Wang JC
    NCI Monogr; 1987; (4):3-6. PubMed ID: 2819727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: quantitation of catalytic activity and DNA cleavage.
    Andrea JE; Adachi K; Morgan AR
    Mol Pharmacol; 1991 Oct; 40(4):495-501. PubMed ID: 1656189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy.
    You F; Gao C
    Curr Top Med Chem; 2019; 19(9):713-729. PubMed ID: 30931860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncoupling of topoisomerase-mediated DNA cleavage and religation.
    Andersen AH; Christiansen K; Westergaard O
    Methods Mol Biol; 2001; 95():101-17. PubMed ID: 11089224
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemical basis for the interactions of type I and type II topoisomerases with DNA.
    Osheroff N
    Pharmacol Ther; 1989; 41(1-2):223-41. PubMed ID: 2540496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
    Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
    Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. DNA lesions as endogenous topoisomerase II poisons.
    Kingma PS; Corbett AH; Burcham PC; Marnett LJ; Osheroff N
    J Biol Chem; 1995 Sep; 270(37):21441-4. PubMed ID: 7665552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.